Sufentanil Sublingual Tablet System: from rationale of use to clinical practice.
Eur Rev Med Pharmacol Sci
; 24(22): 11891-11899, 2020 11.
Article
em En
| MEDLINE
| ID: mdl-33275260
ABSTRACT
The control of post-operative pain in Italy and other western countries is still suboptimal. In recent years, the Sufentanil Sublingual Tablet System (SSTS; Zalviso; AcelRx Pharmaceuticals, Redwood City, CA, USA), which is designed for patient-controlled analgesia (PCA), has entered clinical practice. SSTS enables patients to manage moderate-to-severe acute pain during the first 72 postoperative hours directly in the hospital setting. However, the role of SSTS within the current framework of options for the management of post-operative pain needs to be better established. This paper presents the position on the use of SSTS of a multidisciplinary group of Italian Experts and provides protocols for the use of this device.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Dor Pós-Operatória
/
Analgesia Controlada pelo Paciente
/
Sufentanil
/
Guias de Prática Clínica como Assunto
/
Manejo da Dor
/
Analgésicos Opioides
Tipo de estudo:
Guideline
Limite:
Humans
Idioma:
En
Revista:
Eur Rev Med Pharmacol Sci
Assunto da revista:
FARMACOLOGIA
/
TOXICOLOGIA
Ano de publicação:
2020
Tipo de documento:
Article
País de afiliação:
Itália